NeuroStar TMS Therapy® Clinical Research Clinical trials have proven the efficacy of NeuroStar TMS Therapy in treating patients with major depression who have had not benefited from prior antidepressant medication. In clinical trials the NeuroStar TMS Therapy system was shown to significantly improve patient scores on the Montgomery Asberg Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HAMD-24) scale after 4-6 weeks of treatment1. NeuroStar TMS Therapy was studied in adult patients suffering from Major Depressive Disorder; all of whom had achieved little to no success with previous antidepresant medication therapy. The chart below is a brief description of the indicated patient population:2 Click to enhance NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. In clinical trials, the indicated population had been treated with at least four medication treatment attempts, one of which was at an adequate dose and duration.Click here for full prescribing and safety information NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant treatment. Efficacy has not been established in patients who have failed to receive benefit from two or more prior antidepressant medications at minimal effective dose and duration in the current episode. An Effective Option for Treating Major Depressive Disorder Demonstrated Acute MDD Efficacy in Randomized, Controlled Trial 164 patients from indication patient population Triple-blinded (treater, rater, and patient) 4-6 weeks of TMS monotherapy Patients treated with active NeuroStar TMS Therapy® experienced an average reduction in their depression symptoms of 22.1% compared to a 9% average reduction of depression symptoms in patients receiving inactive treatment2. NeuroStar® treated patients also experienced significant improvement in anxiety and other symptoms associated with depression such as appetite changes, aches and pains, and lack of energy. Acute MDD Efficacy Results in Open-Label Clinical Trial1 43 patients from indicated patient population 6 weeks of TMS monotherapy Approximately half of the patients treated with NeuroStar TMS Therapy® experienced significant improvement in depression symptoms. About a third of the patients treated with NeuroStar TMS Therapy® experienced complete symptom relief at the end of six weeks. View safety data References: Demitrack MA, Thase, ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharm Bull. 2009, 42(2): 5-38. Data on File